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Several genomewide screens have been performed to identify novel loci predisposing to unfavorable serum lipid
levels and coronary heart disease (CHD). We hypothesized that the accumulating data of these screens in different
study populations could be combined to verify which of the identified loci truly harbor susceptibility genes. The
power of this strategy has recently been demonstrated with other complex diseases, such as inflammatory bowel
disease and asthma.We assessed the largely unknown genetic background of CHD by investigating themost common
dyslipidemia predisposing to CHD, familial combined hyperlipidemia (FCHL), affecting 1%–2% of Western pop-
ulations and 10%–20% of families with premature CHD. To be able to perform a combined data analysis, we
unified the diagnostic criteria for FCHL and its component traits and combined the data from two genomewide
scans performed in two populations, the Finns and the Dutch. As a result of our pooled data analysis, we identified
three chromosomal regions, on chromosomes 2p25.1, 9p23, and 16q24.1, exceeding the statistical significance level
of a LOD score 12.0. The 2p25.1 region was detected for the FCHL trait, and the 9p23 and 16q24.1 regions were
detected for the low high-density lipoprotein cholesterol (HDL-C) trait. In addition, the previously recognized 1q21
region also obtained additional support in the other study sample, when the triglyceride trait was used. Analysis
of the 16q24.1 region resulted in a statistically significant LOD score of 3.6 when the data from Finnish families
with low HDL-C were included in the analysis. To search for the underlying gene in the 16q24.1 region, we
investigated a novel functional and positional candidate gene, helix/forkhead transcription factor (FOXC2), by
sequencing and by genotyping of two single-nucleotide polymorphisms in the families.
Introduction
Coronary heart disease (CHD) is the leading cause of
death in Western societies. Unfavorable serum lipid lev-
els, such as high serum total cholesterol (TC), high serum
triglycerides (TGs), and low high-density lipoprotein
cholesterol (HDL-C), are well-known risk factors for
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atherosclerosis and CHD. Consequently, familial dyslip-
idemias featuring these lipid disturbances predispose the
affected family members to CHD. Familial combined
hyperlipidemia (FCHL [MIM 144250]) is one of the
most common familial dyslipidemias, with a population
prevalence of 1%–2% (Goldstein et al. 1973). Although
it has been evident for 30 years that FCHL has a strong
genetic component (Goldstein et al. 1973; Nikkila¨ and
Aro 1973), the actual underlying genes have not yet been
identified. Several encouraging linkage findings have
been reported in different study samples (Pajukanta et
al. 1998, 1999; Aouizerat et al. 1999a, 1999b), but the
identification of causative allelic variants has not pro-
ceeded as rapidly. The slow process of gene identification
in complex traits is most likely caused by several factors,
such as locus and allelic heterogeneity, as well as by
difficulties in assessing the complex phenotypes, which
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can consequently weaken the crucial phenotype-geno-
type link (Weiss and Terwilliger 2000).
The sequencing of the human genome (International
Human Genome Sequencing Consortium 2001; Venter
et al. 2001) has provided the essential tools for fine map-
ping the loci for complex traits. In addition, novel ap-
proaches identifying the causal variants among those in
an associated haplotype are currently under study (Daly
et al. 2001; Johnson et al. 2001; Reich et al. 2001; Rioux
et al. 2001; Gabriel et al. 2002). Haplotype-based meth-
ods, based on association between causal mutations and
the ancestral haplotypes on which they arose, provide a
powerful approach to disease gene mapping. Extended
families with FCHL with refined phenotypic data would
be well-suited for these analytic approaches. However,
the first challenge in fine mapping is to verify those iden-
tified regions that have the highest statistical likelihood
of harboring causative genes. Furthermore, the study
samples originating from different populations are likely
to provide different disease-associated allelic variants and
their haplotypes with varying lengths of linkage dis-
equilibrium (LD) (Pritchard et al. 2001; Gabriel et al.
2002; Van Eerdewegh et al. 2002), which can be con-
sidered as an additional advantage when utilizing study
samples from different populations.
The purpose of the present study is to combine ge-
nome-scan data of two study samples, one originating
from the genetically isolated population of Finland (de
la Chapelle 1993; Peltonen et al. 2000) and the other
from the more mixed population of the Netherlands.
We report here the detailed combined data analysis of
two genome scans for FCHL and its four component
traits: serum TGs, TC, apolipoprotein B (apoB), and
HDL-C. After unifying the diagnostic criteria for FCHL
and its component traits, the most solid evidence for
linkage was obtained between a region on chromosome
16q24.1 and the HDL-C trait. Importantly, this study
also shows which of the other loci identified earlier in
separate genome scans (Aouizerat et al. 1999b; Paju-
kanta et al. 1999) exhibited additional evidence for link-
age in the other study population.
Material and Methods
A total of 560 genotyped individuals from Dutch and
Finnish families were included in the study. Each study
subject provided written informed consent prior to par-
ticipating in the study. All samples were collected in ac-
cordance with the Helsinki Declaration, and the ethics
committees of the participating centers approved the
study design.
Dutch and Finnish Families with FCHL
Eighteen extended Dutch families with FCHL were
ascertained through probands recruited from the lipid
clinic of the Utrecht Academic University Hospital, as
described elsewhere (Dallinga-Thie et al. 1997). These
families were included in the original Dutch genomewide
scan for FCHL (Aouizerat et al. 1999b). The probands
met the following criteria: (1) a primary combined hy-
perlipidemia with varying phenotypic expression, in-
cluding a fasting plasma TC 16.5 mmol/liter or 190th
percentile for age, defined according to tables from the
Lipid Research Clinics, and fasting plasma TGs 12.3
mmol/liter; (2) at least one first-degree relative with a
different hyperlipidemic phenotype; and (3) a positive
family history of premature CHD, defined as myocardial
infarction (MI) or cardiovascular disease before age 60
years. Exclusion criteria for the probands were diabetes,
BMI 130, tendon xanthomas, or type III hyperlipidemia
(apoE2/E2). Of these 18 Dutch families with FCHL, 13,
comprising 173 genotyped individuals, fulfilled the strict
unified diagnostic criteria defined below, and only these
families were analyzed in this study.
A total of 35 extended Finnish families with FCHL
were recruited in the Helsinki, Turku, and Kuopio Uni-
versity Central Hospitals, as described elsewhere (Pa-
jukanta et al. 1998, 1999). These families were included
in the original Finnish genomewide scan for FCHL (Pa-
jukanta et al. 1999). A total of 168 individuals were
genotyped, of which 135 were affected with FCHL. The
“unaffected” individuals were genotyped only to in-
crease phase information and were treated as if their
phenotype were unknown in the statistical analysis, be-
cause of the nondeterministic genotype-phenotype re-
lationship hypothesized for this complex phenotype (see
the “Statistical Analyses” subsection). The inclusion cri-
teria for the probands with FCHL were as follows: (1)
serum TC and/or TGs 190th age/sex-specific Finnish
population percentiles—however, if the proband had
only one elevated lipid trait, a first-degree relative had
to have the combined phenotype (Pajukanta et al. 1998);
(2) age 130 years and !55 years for men and !65 years
for women; and (3) 150% stenosis in one or more cor-
onary arteries, as assessed by coronary angiography. Ex-
clusion criteria for the probands with FCHL were type
1 diabetes mellitus, hepatic or renal disease, and hy-
pothyroidism. Familial hypercholesterolemia was ex-
cluded from each pedigree by determining the low-den-
sity lipoprotein (LDL)–receptor status of the proband,
by the lymphocyte culture method (Cuthbert et al.
1986). Provided that the above-mentioned criteria were
fulfilled, families with at least two affected members
were included in the study, and all the accessible family
members were examined. Family members with FCHL
were scored as “affected” if they had combined hyper-
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lipidemia phenotype IIb or if they had high TC (phe-
notype IIa) or high TGs (phenotype IV), when the Finn-
ish age/sex-specific 90th percentiles for TC and TGs were
used. The criteria used are fully comparable to the orig-
inal criteria by Goldstein et al. (1973) and aim to focus
on families with combined hyperlipidemia phenotype
IIb.
Finnish Families with Low HDL-C
The low–HDL-C study sample was used to increase
linkage information in the 2p25.1, 9p23, and 16q24.1
regions identified in the combined data analysis of the
Dutch and Finnish families with FCHL (see the “Re-
sults” section). This study sample was collected in Hel-
sinki and Turku University Central Hospitals in Finland,
as described in detail elsewhere (Lilja et al. 2002; Soro
et al. 2002). A total of 219 individuals, of whom 104
were affected, from 25 families with well-defined low
HDL-C were included in the study. Inclusion criteria for
the probands with low HDL-C were an age of 30–60
years for men and women, HDL-C levels !10th age/sex-
specific Finnish population percentile, and CHD verified
by either coronary angiography (150% stenosis in one
or more coronary arteries) or MI. Additional lipid cri-
teria for the probands were total TC !6.3 mmol/liter in
men and !6.0 mmol/liter in women, and TGs !2.3
mmol/liter in both sexes. The affected family members
were ascertained for low HDL-C through use of the 10th
Finnish age/sex-specific population percentiles. These
families with low HDL-C have been screened for ABC1
mutations, as described elsewhere (Lilja et al. 2002; Soro
et al. 2002), but no segregating mutations were found.
Low cholesterol efflux has not been excluded.
Biochemical Analyses and Classification of Affection
Status
Serum TC, TGs, apoB, and HDL-C were measured in
the Finnish families with FCHL and low HDL-C, as de-
scribed elsewhere (Pajukanta et al. 1998, 1999). The data
collection, laboratory measurements, and phenotype de-
terminations for the Finnish families with low HDL-C
and FCHL were performed in the same center, making
the clinical and biochemical data in these two samples
fully compatible. In the Dutch families with FCHL, lip-
ids and apolipoproteins were quantified by methods de-
scribed elsewhere (Castro Cabezas et al. 1993; Dallinga-
Thie et al. 1996). Probands or hyperlipidemic relatives
who used lipid-lowering drugs were studied after their
lipid lowering treatment was withheld for 3 wk in the
Dutch study sample and for 4 wk in the Finnish study
samples.
To maximize the similarity of ascertainment between
the two FCHL cohorts, we used the age/sex-specific 90th
population percentiles of TC, TGs, and apoB, as well as
the 10th percentile of HDL-C, to classify both the Dutch
and Finnish families. Accordingly, the Dutch families
were first redefined using the same diagnostic criteria
outlined above for the Finnish families. Because the age/
sex-specific lipid percentiles are publicly available only
for the Finnish population (Porkka et al. 1994; Vartiai-
nen et al. 1994), the Finnish percentiles were also used
to classify the Dutch families. The cutoffs for the Finnish
90th age/sex-specific percentile values for TC, TGs, and
apoB are available from the National Public Health In-
stitute, Finland, Web site, and the cutoffs for the Finnish
10th age/sex-specific percentile values for HDL-C have
been published elsewhere (Lilja et al. 2002). Since the
lipid levels in the Finnish population are, on aver-
age, somewhat higher than the Dutch, especially TGs
(T.W.A.dB., unpublished data), the Finnish criteria used
for the Dutch families can be considered more stringent
than if population averages from the Netherlands were
used, resulting in a conservative analysis of the Dutch
families with FCHL. Of the 18 Dutch families with
FCHL, 13, comprising 173 genotyped individuals,
matched the strict criteria defined above, and only these
families were analyzed in this study. In the Dutch families
with FCHL, the numbers of individuals classified as af-
fected with FCHL, elevated apoB, elevated TGs, elevated
TC, and low HDL-C were 55, 72, 47, 56, and 37, re-
spectively. In the Finnish families with FCHL, the cor-
responding numbers were 135, 107, 96, 107, and 64.
The original genotyping strategy and numbers of af-
fected individuals differed among the Finnish and Dutch
FCHL samples. In the Finnish families with FCHL, 135
of the 168 genotyped individuals were affected with
FCHL (Pajukanta et al. 1999). The total number of in-
dividuals in these 35 families is 501, resulting in 27%
affected subjects with FCHL. In the Dutch study sample,
173 of 373 individuals were genotyped, and 55 of these
173 were affected with FCHL (15%), since the geno-
typing strategy for the Dutch sample concentrated on
the affected individuals and their first-degree relatives in
the available nuclear families (Aouizerat et al. 1999b).
Combining these samples through use of the strict Finn-
ish criteria has made the study samples more consistent,
but the effect of this difference in genotyping strategies
on the analytic results is not clear.
Although LDL-C is an important component of
FCHL, it was not included in the diagnostic criteria
when ascertaining these Dutch or Finnish families with
FCHL or in the original study, by Goldstein et al.
(1973), describing the FCHL disorder. One reason is
the significant hypertriglyceridemia associated with
FCHL. The Friedewald formula is not recommend-
ed when TGs are 1400 mg/dl—that is, 4.4 mmol/li-
ter—which is often the case with hypertriglyceridemic
family members. In addition, the population percentile
points of LDL-C could not be estimated when including
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this factor, since we currently don’t have population
percentiles for LDL-C.
We recognize that quantitative traits usually provide
more linkage information than binary ones. However,
ascertainment of these families with FCHL via a proband
and an additional first-degree relative with high TC or
TGs and the genotyping strategy of the Finnish families
with FCHL, which was designed to maximize the in-
formation obtained from the affected subjects with only
necessary unaffected relatives genotyped for phase in-
formation, resulted in limited variation in serum TC and
TG levels for effective QTL analysis. Since these con-
straints would allow very little power to be gained from
a continuous trait analysis, we chose to limit our anal-
yses to binary traits, as explained in the “Statistical Anal-
yses” subsection.
Genotyping of the Markers and Sequencing
of the FOXC2 Gene
In the two genome scans, ∼385 microsatellite markers
included in the Weber screening set version 6 (Sheffield
et al. 1995) and spaced, on average, 10.0 cM apart were
genotyped. The separate genome scans previously con-
ducted in the Dutch and Finnish families with FCHL
have been reported elsewhere (Aouizerat et al. 1999b;
Pajukanta et al. 1999). In addition, to maximize the
linkage information in potentially important regions, we
genotyped the peak markers in the missing study sample
in cases where the marker was genotyped in only one
study sample. Furthermore, two additional markers for
chromosome 16q were genotyped in both FCHL study
samples. Thus, markers D1S104, D1S2844, D2S243,
D16S518, D16S422, and D16S505 were genotyped in
the Dutch families with FCHL; markers D15S655,
D16S516, and D16S507 were genotyped in the Finnish
families with FCHL; and markers D16S3096 and
D16S3040 were genotyped in both FCHL study samples.
The fluorescently labeled PCR products were electro-
phoretically separated on an automated DNA sequencer
(ABI 377XL; Perkin Elmer), with analysis by Applied
Biosystems Genescan 2.1 software (Perkin Elmer). The
order of the markers for the regions on 2p25.1, 9p23,
and 16q24.1 was based on the genetic maps of the
Marshfield Medical Research Foundation (Center for
Medical Genetics Web site).
The entire human winged helix/forkhead transcription
factor gene (FOXC2 [MIM 602402]) and a 760-bp region
upstream from the 5′ end of the FOXC2 gene were se-
quenced in the probands of the families contributing to
the linkage signal (see the “Results” section). The 760-
bp region was selected by comparing the 10-kb sequence
from both ends of the FOXC2 gene between mouse and
human, using the VISTA program (VISTA Home Page).
The samples were amplified by PCR for the automated
DNA sequencer ABI 377XL (Perkin Elmer). Purification
of the PCR product was performed with exonuclease I
(Amersham Life Sciences) and shrimp alkaline phospha-
tase (Amersham Life Sciences). Sequencing was performed
in both directions, according to the Big Dye Terminator
Cycle Sequencing protocol (PE Biosystems), with minor
modifications. Sequencing Analysis software, version 3.2
(PE Biosystems), was used to perform the initial base call-
ing of the sequencing traces. Sequence contigs were as-
sembled through use of Sequencer software (GeneCodes).
The dbSNP (dbSNP Home Page) and Celera (Celera Web
site) databases were also used to find polymorphisms in
the FOXC2 gene. We applied a pyrosequencing technique
for SNP genotyping, using the PSQ96 instrument and the
SNP Reagent kit (Pyrosequencing AB), as described else-
where (Pielberg et al. 2002). Primers for PCR were de-
signed through use of the Primer3 program, available at
the Whitehead Institute for Biomedical Research Web site.
Detection primers for pyrosequencing were designed
through use of the SNP Primer Design Software, version
1.01 (Pyrosequencing AB). Oligo Analyzer 2.5, available
at the Integrated DNA Technologies Web site, was used
to calculate the melting temperature of the primers and
to check all the primers for primer dimers and hairpins,
to prevent possible background signals in the SNP
genotyping.
Statistical Analyses
Statistical analyses were conducted according to the
strategy described below. The genomewide set of mark-
ers genotyped earlier in the Finnish and Dutch families
with FCHL (Aouizerat et al. 1999b; Pajukanta et al.
1999) were analyzed with five binary traits—FCHL and
its component traits TC, TGs, apoB, and HDL-C—
through use of the unified diagnostic criteria described
in detail above. The Finnish families with low HDL-C
were analyzed only for the low–HDL-C trait and only
in the three regions on 2p25.1, 9p23, and 16q24.1 iden-
tified in the combined analysis of the Dutch and Finnish
families with FCHL. The purpose was to increase the
linkage information in potentially interesting regions. In
the Dutch and Finnish families with FCHL, the FCHL
component traits—TC, TGs, apoB, and HDL-C—were
analyzed in addition to the FCHL trait, to identify any
loci predisposing to one of those traits individually that
might not be involved in the more extreme FCHL phe-
notype. Two-point linkage analyses using parametric
and nonparametric affected-sib-pair (ASP) analyses were
performed for the genomewide set of markers in the
combined sample of the Finnish and Dutch families with
FCHL. Multipoint analyses were performed only for the
three regions identified by two-point LOD scores 12.0.
Multipoint analysis was restricted to these regions be-
cause of possible undetected problems of genotyping and
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map errors. For the 16q region, a parametric four-point
linkage analysis was also performed by analyzing trios
of adjacent markers with the Mlink program (Lathrop
et al. 1984). In this analysis, the tightly linked markers
are placed in a fixed order, and the disease locus is al-
lowed to vary outside the marker map. This strategy
was used as an alternative to multipoint analysis with
flanking markers (moving the disease across the map),
because of the latter method’s known propensity for
false exclusions (Risch and Giuffra 1992). The main pur-
pose was to score meioses uninformative for one of the
markers for adjacent markers (analogous to the previous
studies [Terwilliger and Ott 1993], with the benefit of
controlling for the intermarker recombination fractions),
thus allowing all meioses on the pedigrees to be scored
in this analysis (Pajukanta et al. 1998). Affecteds-only
parametric and nonparametric analyses were employed
to better model the unknown mode of inheritance of
FCHL. To circumvent problems of incomplete pene-
trance and genetic ambiguity of the “unaffected” phe-
notype, we used an affecteds-only strategy, by coding
the family members as either “affected” or “unknown”
on the basis of the age/sex-specific 90th percentile thresh-
olds for TC, TGs, and apoB and the 10th percentile
threshold for HDL-C. The unaffected subjects were ge-
notyped only to increase phase information and were
treated as if their phenotypes were unknown (Pajukanta
et al. 1998, 1999). The parametric linkage analyses were
performed with both dominant and recessive modes of
inheritance, with gene frequencies of 0.6% and 10.95%,
respectively, reflecting an estimated population preva-
lence of ∼1%–2% for FCHL (Goldstein et al. 1973).
The Mlink program of the Linkage package (Lathrop
et al. 1984), version Fastlink 4.1P (Cottingham et al.
1993; Scha¨ffer et al. 1994), was used, with the help of
the Analyze package (Go¨ring and Terwilliger 2000a), to
perform the parametric linkage analyses. The ASP analysis
was performed using the Sibpair program (Kuokkanen et
al. 1996) of the Analyze package (Go¨ring and Terwilliger
2000a). For each marker, the allele frequencies were es-
timated from all individuals by the Downfreq program
(Go¨ring and Terwilliger 2000b). The whole genomewide
scan of each trait was run in a single computer analysis
through use of the Autoscan program, available at the
authors’ Web site (UCLA Human Genetics Autoscan 1.0
Web site). Multipoint analyses were performed with the
SimWalk2 program, version 2.82 (Sobel and Lange 1996).
In the nonparametric linkage analysis (NPL) of the
SimWalk2 program, statistic A is most powerful at de-
tecting linkage to a recessive trait, statistic B is most pow-
erful at detecting linkage to a dominant trait, and statistics
C and D are more general statistics indicating whether a
few founder alleles are overrepresented among the af-
fected individuals. The Mendelian errors were checked
with the PedCheck program (O’Connell and Weeks
1998). Genetic heterogeneity was tested using the Homog
program (Ott 1991) of the Analyze package (Go¨ring and
Terwilliger 2000a). The SNPs in the FOXC2 gene were
tested for association through use of the gamete compe-
tition test (Sinsheimer et al. 2000). The gamete compe-
tition test (Sinsheimer et al. 2000) is a genetic application
of the Bradley-Terry model, originally designed for the
ranking of sports teams. It provides a parametric exten-
sion of the transmission/disequilibrium test and views
transmission of marker alleles to affected children as a
contest between the alleles, making effective use of full
pedigree data. Furthermore, the gamete competition
model readily extends to two linked markers (Sinsheimer
et al. 2000), enabling simultaneous analysis of multiple
SNPs in a gene.
Results
We performed a combined data analysis of Finnish and
Dutch FCHL genome scans, through use of unified di-
agnostic criteria for the analyzed phenotypic lipid traits.
In addition to the FCHL trait, four component traits of
the disorder—TGs, TC, apoB, and HDL-C—were an-
alyzed. For each chromosome, figure 1 summarizes the
results of the two-point linkage analysis with the FCHL
trait in the Finnish, Dutch, and combined study samples.
In addition, the complete two-point linkage results for
all markers are available, at the authors’ Web site (UCLA
Human Genetics Web site), for all five lipid traits. For
comparison among the methods, P values have been in-
cluded in parentheses for all results presented in the fol-
lowing paragraphs of this section.
Regions Where the Combined Data Analysis Provided
LOD Scores 12.0
The combined data analysis provided evidence of link-
age to three regions, on 2p25.1, 9p23, and 16q24.1,
resulting in LOD scores of 2.2 ( ), 2.1 (Pp .0007 Pp
), and 3.6 ( ), respectively. The 2p25.1.0009 Pp .00002
region was detected for the FCHL trait, and the 9p23
and 16q24.1 regions were detected for the low–HDL-C
trait (tables 1 and 2).
On chromosome 16q, the highest two-point results for
low HDL-C were 0.8 ( ), 1.1 ( ), and 1.7Pp .03 Pp .01
( ), in the Dutch, Finnish, and combined studyPp .003
samples, respectively (table 1). The multipoint results
( ) of the NPL of the SimWalk2 program log [P value]10
for each study group with the low HDL-C trait were 2.1
( ), 1.1 ( ), and 2.7 ( ), respec-Pp .007 Pp .07 Pp .002
tively (table 1). The parametric multipoint analysis also
provided support for low HDL-C in the combined data
analysis of the Finnish and Dutch families with FCHL,
with a location score of 3.2 ( ) when allowingPp .0001
for heterogeneity (a value p 0.75) and with a location
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Figure 1 Two-point maximum LOD scores (from parametric linkage analysis with either a dominant or recessive mode of inheritance or
from ASP analysis) obtained for each chromosome in different study samples, using the FCHL trait. Gray columns show the two-point results
for the Dutch families with FCHL, white columns show the results for the Finnish families with FCHL, and black columns show the results
for the combined data analysis of the Dutch and Finnish families with FCHL. The marker resulting in the highest LOD score on each chromosome
is indicated for each study group, and its position from pter (in cM) is given in parentheses. The complete genomewide two-point results are
available for all five traits at the authors’ Web site.
score of 2.2 under homogeneity ( ), suggestingPp .0007
a more recessive type of inheritance model for the trait
(fig. 2). Furthermore, since the three regions on 2p25.1,
9p23, and 16q24.1 were detected with either the HDL-
C trait or a trait known to be closely correlated with HDL-
C, we also analyzed these three regions by combining the
genomewide scan data from Finnish families with low
HDL-C (Soro et al. 2002). These Finnish families with
low HDL-C were analyzed only for the low–HDL-C trait
and only in the three regions on 2p25.1, 9p23, and
16q24.1 identified in the combined analysis of the Dutch
and Finnish families with FCHL. When the data from the
families with low HDL-C were included in the analysis,
the 16q24.1 region produced a nonparametric multipoint
score of 3.0 ( ), by means of the NPL analysisPp .0009
of the SimWalk2 program, and a parametric multipoint
LOD score of 3.4 (a value p 0.50) ( ), byPp .00007
means of a parametric location score analysis from the
SimWalk2 program for the low–HDL-C trait (table 1 and
fig. 2). For a p 1.00, the largest overall location score
was 2.3 ( ). This result suggests that there isPp .0006
locus heterogeneity among the families, with approxi-
mately half of them exhibiting linkage to this chromo-
somal region. Figure 2 shows the parametric multipoint
results for chromosome 16q24.1, when the HDL-C trait
is used for each study sample. The LOD scores of the
other regions on 2p25.1 and 9p23 remained !2.0 when
the families with low HDL-C were included in the
analysis.
A parametric four-point linkage analysis was also per-
formed on 16q24.1, by analyzing trios of adjacent mark-
ers and the HDL-C trait in the combined analysis of the
Finnish and Dutch families with FCHL and Finnish fam-
ilies with low HDL-C, through use of the low–HDL-C
trait. The maximum four-point LOD score of 3.6 (re-
combination fraction [v]p 0.08) ( ) was ob-Pp .00002
Pajukanta et al.: A Locus for HDL-C Levels on Chromosome 16q 909
Table 1
Two-Point and Multipoint Results of the Chromosome 16q24.1 Region for the HDL-C Trait in Dutch and Finnish Families with FCHL,
in the Combined Analysis of Families with FCHL, and in the Combined Analysis of Families with FCHL and Low HDL-C
MARKER
DISTANCE
FROM
D16S518
(cM)
DUTCHa FINNSb COMBINEDc COMBINED  FAMILIES WITH HDL-Cd
LOD MP LOD MP LOD MP LOD MP PMP
D16S518 .0 .2 (.2) 1.0 (.1) 1.1 (.01) .9 (.1) 1.3 (.007) 1.4 (.04) 1.3 (.007) 1.7 (.02) 3.4 (.00007)
D16S3096 4.4 .5 (.06) 2.1 (.007) 1.0 (.02) 1.1 (.07) 1.5 (.004) 2.7 (.002) .9 (.02) 3.0 (.0009) 3.4 (.00007)
D16S516 5.3 .6 (.05) 2.0 (.01) .1 (.2) 1.1 (.08) .6 (.05) 2.3 (.005) .6 (.05) 2.9 (.001) 2.9 (.0002)
D16S3040 9.4 .4 (.09) 1.6 (.02) .0 (.5) .8 (.2) .2 (.2) 1.7 (.02) .4 (.09) 2.5 (.003) 2.4 (.0008)
D16S507 10.1 .6 (.05) 2.0 (.01) 1.0 (.02) .8 (.1) 1.7 (.003) 2.0 (.01) 1.7 (.003) 2.7 (.002) 2.7 (.0004)
D16S505 13.9 .5 (.06) 1.8 (.02) .0 (.5) .6 (.3) .3 (.1) 1.5 (.03) 1.5 (.004) 2.5 (.003) 2.0 (.002)
D16S3091 16.0 .1 (.2) .7 (.2) .1 (.2) .3 (.5) .1 (.2) .7 (.2) 1.4 (.006) 1.5 (.03) .6 (.07)
D16S422 16.1 .8 (.03) .7 (.2) .0 (.5) .1 (.7) .5 (.06) .4 (.4) .5 (.06) 1.2 (.07) .4 (.1)
D16S402 18.5 .7 (.04) 1.0 (.09) .7 (.04) .6 (.3) .5 (.06) 1.1 (.08) .3 (.2)
D16S3061 26.4 .0 (.50) .6 (.2) .0 (.6)
NOTE.—For comparison among the methods, P values have been included for LOD scores, location scores, and scores (in log (P value)10
parentheses). LOD p the two-point maximum LOD score of the parametric linkage analysis using a recessive mode of inheritance; MP p
nonparametric multipoint results ( ) of the NPL analysis using the SimWalk2 program, statistic C. The results of the other log [P value]10
statistics of NPL analysis were consistent with those of statistic C. PMPp parametric multipoint location scores using the SimWalk2 program
with a recessive mode of inheritance and allowing for heterogeneity.
a Study sample of the Dutch families with FCHL.
b Finnish families with FCHL.
c Dutch and Finnish families with FCHL.
d Dutch and Finnish families with FCHL as well as the Finnish families with low HDL-C.
served with markers D16S507-D16S505-D16S3091,
suggesting that the most significant evidence of linkage
is obtained in this 6-cM region. Furthermore, the highest
two-point LOD score, 2.0 ( ), for 16q24.1, wasPp .001
obtained in the ASP analysis with marker D16S505,
which is located in the middle of this trio.
The regions on chromosomes 2p25.1 and 9p23
showed suggestive evidence of linkage in the pooled data
analyses, with the maximum LOD scores 2.2 (Pp
) and 2.1 ( ), respectively, when the.0007 Pp .0009
FCHL and low HDL-C traits were used (table 2). The
addition of the Finnish families with low HDL-C did
not improve these results. In the case of the 2p25.1 re-
gion (table 2), the most significant result of the combined
study sample was obtained with the FCHL trait and
marker D2S423 (LOD score 2.2 [ ]). However,Pp .0007
in the Dutch study sample, the segregating trait was TGs,
resulting in a LOD score of 2.3 ( ) with markerPp .0006
D2S2952, located 4.2 cM from D2S423. In the Finns,
the trait with the strongest linkage was HDL-C, yielding
an ASP LOD score of 3.4 ( ) with markerPp .00004
D2S423. Thus, the combined data analysis did not result
in statistically significant evidence for linkage, although
both study samples showed some evidence for linkage
with chromosomal region 2p25.1.
Results for Other Chromosomal Regions Previously
Linked with FCHL, in Either the Dutch or Finnish
Families with FCHL
To date, two genomewide scans have been published
for FCHL. Five loci, on chromosomes 1q21, 2q31,
10p11.2, 10q11.2-10qter, and 21q21, were identified in
the Finnish studies (Pajukanta et al. 1998, 1999), and
four loci, on chromosomes 2p, 11p, 16q, and 19q, were
identified in the Dutch scan (Aouizerat et al. 1999b).
The regions on 1q21, 2p, 11p, and 16q were detected
for the FCHL trait; those on 2q31 and 10p11.2 were
detected for TGs; that on 10q11.2-10qter was detected
for TC; and that on 21q21 was detected for apoB. In
addition, regions on 2p, 8q, 16q, and 20q have been
identified for low HDL-C in the Finnish families with
FCHL (Soro et al. 2002), as well as a region on 1p for
apoB in the Dutch families with FCHL (Allayee et al.
2002). Of these regions, those on chromosomes 2p and
16q could be detected in the combined data analysis of
the present study when the low–HDL-C and FCHL traits
were used, as described above. In addition, chromoso-
mal regions on 1q21 and 2q31 were detected, with some
statistical significance, when the TG trait in the Dutch
study sample was used as well, although the combined
data analysis did not provide statistically significant ev-
idence for linkage. These results are described in detail
below.
On chromosome 1q21, the highest two-point LOD
score in the Dutch families with FCHL was 1.8 (Pp
), detected with the TG trait and with marker.002
D1S1679, as reported elsewhere (Allayee et al. 2002).
Marker D1S1679 is located !5 cM centromeric from the
peak linkage markers of the Finnish study sample,
D1S104 and D1S1677. In the current study, these peak
linkage markers of the Finnish study sample were also
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Table 2
Two-Point and Multipoint Results of the 2p25.1 and 9p23 Regions
LINKAGE AND MARKER
DISTANCE
FROM
FIRST
MARKER
(cM)
DUTCHa FINNSb COMBINEDc
LOD ASP LOD ASP LOD ASP MPd
2p25.1 region and FCHL trait:
D2S2952 0 .6 1.1 (.01) 1.0 (.02) .6 1.7 (.003) 1.6 (.004) 1.9 (.01)
D2S423 4.22 .2 .4 2.3 (.0006) .8 2.2 (.0007) 1.2 (.009) 1.5 (.03)
D2S1400 9.72 .0 .6 .1 .1 .1 .4 1.2 (.06)
2p25.1 region and TG trait:
D2S2952 0 .8 2.3 (.0006) .5 .3 1.3 (.007) 1.6 (.003) 1.8 (.02)
D2S423 4.22 .6 1.0 (.01) .7 .4 1.2 (.009) 1.4 (.005) 1.6 (.03)
D2S1400 9.72 .8 1.7 (.003) .5 .6 1.2 (.009) 1.8 (.002) 1.4 (.04)
2p25.1 region and HDL-C trait:
D2S2952 0 .0 .0 1.2 (.009) .7 .2 .2 .9
D2S423 4.22 .0 .0 2.6 (.0003) 3.4 (.00004) 1.2 (.009) 1.4 (.005) 1.2 (.07)
D2S1400 9.72 .7 .0 .7 .4 1.2 (.009) .2 1.0 (.1)
9p23 region and HDL-C trait:
D9S2169 0 .3 .0 .8 .2 1.0 (.02) .1 1.4 (.04)
GATA175H06 3.83 .6 .6 .0 .0 .4 .3 1.6 (.03)
D9S921 7.65 1.7 (.003) .1 .1 .2 2.1 (.0009) .4 1.8 (.01)
D9S925 18.01 .0 .0 .0 .0 .0 .0 1.0 (.1)
NOTE.—The 2p25.1 region is shown with three phenotypes to demonstrate the effect of the phenotype. LOD p the two-point maximum
LOD score of the parametric linkage analysis using a recessive mode of inheritance; ASP p the LOD score of the two-point affected sib-pair
analysis. For comparison among the methods, P values have been included for LOD scores and scores 11.0 (in parentheses). log (P value)10
The LOD scores detected in the parametric (LOD) and nonparametric (ASP) two-point analyses are directly comparable.
a Study sample of the Dutch families with FCHL.
b Finnish families with FCHL.
c Dutch and Finnish families with FCHL.
d Nonparametric multipoint results ( ) of the NPL analysis using the SimWalk2 program. SimWalk statistic A was used for log [P value]10
the analysis of linkage between the 2p25.1 region and both the FCHL and TG traits; statistic D was used for the analysis of linkage between
the 2p25.1 region and the HDL-C trait; and statistic B was used for the analysis of linkage between the 9p23 region and the HDL-C trait.
Although the best-fitting statistics for each region and trait are shown here, the results of all statistics in the NPL analysis were consistent with
these.
genotyped and analyzed in the Dutch study sample (table
3). In the Dutch study sample, they resulted in maximum
two-point LOD scores of 0.5 ( ). The overallPp .06
multipoint NPL result for TGs was 1.1 ( ) in thePp .09
Dutch study sample. However, the combined data anal-
ysis resulted in a lower LOD score of 2.8 ( )Pp .0002
for TGs, when compared with the result in the Finnish
families with FCHL (LOD score of 3.1 [ ])Pp .00008
(table 3). It is worth noting that, in the Finnish study
sample, the strongest signal for this region was detected
with the FCHL trait (Pajukanta et al. 1998).
On chromosome 2q31, the inclusion of the Dutch
families resulted in LOD scores of ∼1.0 with consecutive
markers when the TG trait was used, shifting the region
10 cM toward the telomeric end of the chromosome.
Accordingly, in the Dutch study sample, the highest two-
point LOD score, 1.3 ( ), was obtained withPp .007
marker D2S1649, located 5 cM telomeric from the Finn-
ish peak linkage markers. In the Finnish study sample,
the strongest signal was also detected with the TG trait
(ASP LOD score 2.2 [ ]).Pp .0007
On chromosome 10p11.2, the highest two-point LOD
score, of 3.3 ( ; ), was obtained withvp 0.0 Pp .00005
marker D10S1220 and the TG trait in the combined
data analysis. In the separate analyses, the Dutch study
sample provided a LOD score of 0.5 ( ;vp 0.0 Pp
), and the Finnish families with FCHL provided a.06
LOD score of 2.6 ( ; ). Further, whenvp 0.0 Pp .0003
the additional Finnish families with FCHL, genotyped
for this region in the dense mapping of the original ge-
nome scan (Pajukanta et al. 1999), were included in the
current study, we obtained a LOD score of 3.9 (vp
; ) with D10S1220 for TGs. However,0.0 Pp .00001
the adjacent markers gave two-point LOD scores !1.0
for this region in the combined analysis, as did the mul-
tipoint analysis.
The chromosome 11p region resulted in a two-point
maximum LOD score of 2.1 ( ) with markerPp .0009
D11S1999 in the Dutch study sample when the FCHL
trait was used, whereas, in the Finnish study sample, the
markers for the 11p region did not yield two-point LOD
scores 10.5 with any of the five investigated traits. Anal-
ysis of the apoB region on 1p that was recently identified
in the Dutch families with FCHL (Allayee et al. 2002)
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Table 3
Two-Point Linkage Results for Chromosome 1q21
in the Dutch Families with FCHL, Finnish Families
with FCHL, and the Combined Analysis, Using the TG
Trait
MARKER
DISTANCE
FROM
D1S1679
(cM)
LOD/ASPa
Dutch Finns Combined
D1S1679 0 1.8/.4 .2/.2 1.9/.6
D1S2844 4.2 .4/.2 1.2/1.3 1.3/1.4
D1S104 4.8 .5/.1 3.1/2.2 2.8/1.9
D1S1677 4.8 .0/.5 .4/1.0 .1/1.2
D1S426 7.0 .0/.0 .9/1.0 .5/.9
aLOD p the highest two-point maximum LOD score
of the parametric linkage analysis using a dominant mode
of inheritance; ASP p the LOD score of the two-point
ASP analysis. The LOD scores produced by both methods
are directly comparable.
Figure 2 Parametric multipoint results for chromosome 16q24.1, obtained using the HDL-C trait and a recessive mode of inheritance.
The analysis was performed using the “Location Score” option of the SimWalk2 program and allowing for heterogeneity. Dutch p the study
group of the Dutch families with FCHL; Finns p the Finnish families with FCHL; combined p the Dutch and Finnish families with FCHL;
combined  HDL-C p the Dutch and Finnish families with FCHL, as well as the Finnish families with low HDL-C. The a values for the peak
location scores of the Dutch, Finns, combined, and combined  HDL-C families were 0.80, 0.70, 0.75, and 0.50, respectively.
resulted in reduced evidence for linkage with the apoB
trait when the Finnish families with FCHL were in-
cluded. The LOD score with the peak marker D1S1665
and the apoB trait decreased from 3.8 ( ) inPp .00001
the Dutch study sample to 2.0 ( ) in the com-Pp .001
bined study sample, and the adjacent markers also re-
mained nonsignificant. In addition, no other regions
with LOD scores 12.0 were detected for the apoB or TC
trait in the combined analysis of the Dutch and Finnish
families with FCHL, and none of the other regions de-
tected earlier in the Finnish or Dutch families with FCHL
provided additional support for linkage in the combined
data analysis.
The FOXC2 Gene Resides on Chromosome 16q24.1
An interesting positional candidate gene residing in the
linked 16q region is the human winged helix/forkhead
transcription factor gene, FOXC2,which has just recently
been shown to play a role in hypertriglyceridemia,obesity,
and diet-induced insulin resistance in mice (Cederberg et
al. 2001). Since FOXC2 is a small gene (1,506 bp) with
only one exon, we sequenced the entire gene, as well as
750 bp of the 5′ flanking region. It is noteworthy that this
750-bp region was found to be highly conserved between
mouse and human (fig. 3). The region may thus represent
the promoter or another potentially functionally impor-
tant region of the FOXC2 gene. For sequencing, we se-
lected the probands of the families that provided a LOD
score 10.5 in the multipoint location score analysis for
chromosome 16q24.1. Consequently, 17 probands were
included in the sequence analysis from four Dutch families
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Figure 3 Conservation between mouse and human sequences in the genomic region of the FOXC2 gene. The SNP located in the putative
promoter of the FOXC2 gene (512) is shown in detail. The comparison between the genomic sequences of human and mouse was performed
using the VISTA program.
with FCHL, five Finnish families with FCHL, and eight
Finnish families with low HDL-C. Although no coding
variants were identified, two variants were found in the
conserved 5′ region upstream of the FOXC2 gene (fig. 3):
nine probands had a TrC variation (eight heterozygotes
and one rare-allele homozygote) at position 512, up-
stream from FOXC2, and two probands had a GrT var-
iant (two heterozygotes) at position 350. We selected
the more common –512 SNP, located in a region that
is well conserved between mouse and human, and anoth-
er SNP (hCV2849496), found using the Celera data-
base, for genotyping in the families. The latter SNP
(hCV2849496) is located 6,452 bp downstream from the
3′ end of the FOXC2 gene. Given the small sample size
when independent affected individuals are selected from
these extended families with FCHL and low HDL-C, we
chose to test the SNP associations by using the gamete
competition test only with haplotype information. Thus,
to obtain more information for the association analysis,
we employed the gamete competition test to test for as-
sociation in a combined analysis of the two SNPs simul-
taneously. As a result, evidence for association (Pp
) was obtained with the TG trait, suggesting that the.005
allelic variants of FOXC2 may regulate the TG and/or
HDL-C levels in the families with FCHL. We found that
the haplotype combination 1-1 (i.e., the common allele
of the 512 SNP and the common allele of the
hCV2849496 SNP) was more often transmitted to the
affected subjects in the combined analysis of all families.
With the low–HDL-C trait, the corresponding P value
remained nonsignificant ( ).P 1 .05
Discussion
We performed a combined data analysis of Dutch and
Finnish genomewide scans for FCHL to identify the
regions most likely to harbor allelic variants for this
complex lipid disorder. Three regions, on chromosomes
16q24.1, 2p25.1, and 9p23, with maximum LOD scores
of 3.6, 2.2, and 2.1, respectively, were detected in which
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the evidence for linkage emerged from the combined
study sample (tables 1 and 2; fig. 2). The 9p23 and
16q24.1 regions were both detected for the low–HDL-
C trait, and the 2p25.1 region was detected for the
FCHL trait. In addition, the previously identified FCHL
region on 1q21 (Pajukanta et al. 1998) also showed
some evidence for linkage of TGs in the Dutch study
sample, although the combined data analysis did not
provide additional support, as is discussed in detail
below.
In the earlier separate genome scans, five loci, on
chromosomes 1q21, 2q31, 10p11.2, 10q11.2-10qter,
and 21q21, were identified in the Finnish families with
FCHL (Pajukanta et al. 1998, 1999), and four loci, on
chromosomes 2p, 11p, 16q, and 19q, were identified in
the Dutch families with FCHL (Aouizerat et al. 1999b;
reviewed by Eurlings et al. 2001). In addition, regions
on 2p, 8q, 16q, and 20q have been detected for low
HDL-C in the Finnish families with FCHL (Soro et al.
2002), and a region on 1p has been detected for apoB
in the Dutch families with FCHL (Allayee et al. 2002).
To date, these are the published genomewide scans for
FCHL. The combined data analysis of the present study
provided significant evidence for linkage, especially with
the 16q24.1 region, resulting in a multipoint LOD score
of 3.6 for low HDL-C. In the earlier Dutch FCHL ge-
nome scan, the multipoint LOD score for this same
region was 1.4, the peak occurring within this very same
interval over marker D16S402 for FCHL (Aouizerat et
al. 1999b). In the Finnish families with FCHL, this re-
gion previously resulted in a two-point LOD score of
1.2 with marker D16S2624 when the apoB trait was
used and in a two-point LOD score of 1.0 with marker
D16S518 when the low–HDL-C trait was used (Paju-
kanta et al. 1999; Soro et al. 2002). In the Finnish
families with low HDL-C, the highest two-point LOD
score for this region was 1.9, with marker D16S3091
(Soro et al. 2002), but the multipoint NPL score for
low HDL-C remained !1.5 in the Finnish families with
FCHL and low HDL-C (Soro et al. 2002). The 9p23
region previously resulted in a two-point LOD score of
1.3 with the FCHL trait in the Finnish families with
FCHL (Pajukanta et al. 1999). In the current study, the
addition of the Dutch families provided some support
for this region (table 2).
Interpretation of the results of the combined data
analysis for the 1q21 and 2p25.1 regions is more com-
plex. Chromosome 1q21 previously provided a two-
point maximum LOD score of 3.5 and a parametric
three-point LOD score of 5.9 with the FCHL trait in
the Finnish families with FCHL (Pajukanta et al. 1998),
whereas, in the Dutch families, the TG trait produced
the highest LOD score, 1.8, with marker D1S1679, re-
siding in a region close to the Finnish peak linkage
markers, and the results of the combined linkage anal-
ysis remained lower than in the Finnish families with
FCHL separately (table 3). The 2p25.1 region provides
a similar kind of example, with the HDL-C trait pro-
ducing the strongest evidence for linkage in the Finnish
and the TG trait in the Dutch families with FCHL with
different markers (table 2). Thus, this region did not
result in statistically significant evidence for linkage in
the combined data analysis, although both study sam-
ples provided support for this region separately. These
somewhat ambiguous results most likely reflect several
underlying features of the data, such as the original
ascertainments of the two study samples, potentially
different causative variants and the ancestral haplotypes
on which they arose in the Finnish and Dutch popu-
lations, and varying marker informativeness combined
with unavoidable genotyping errors. Because of these
factors, it is not unusual that two study samples do not
peak at the very same location (Lander and Shork 1994;
Roberts et al. 1999; Ekelund et al. 2000). Consequently,
we interpret this to imply that the 1q21 and 2p25.1
regions are candidates for fine-mapping efforts using
larger study samples. Furthermore, the 1q21 region has
been replicated in families with FCHL from other pop-
ulations (Coon et al. 2000; Pei et al. 2000). Importantly,
the same markers in the 1q21 region have also been
linked to type 2 diabetes in several earlier studies (Han-
son et al. 1998; Elbein et al. 1999; Vionnet et al. 2000;
Wiltshire et al. 2001), including a Finnish study sample
(Watanabe et al. 2000). This may indicate that there
are one or more genes in this region, the different var-
iants of which are causative for FCHL and type 2 di-
abetes. This is a plausible explanation, since the FCHL
phenotype clearly overlaps with type 2 diabetes. Inter-
estingly, the 1q21 region was also recently linked to
lipoprotein a in families with CHD of western European
origin (Broeckel et al. 2002).
The purpose of the present study was to combine
genome-scan data to accelerate the slow process of gene
identification in complex lipid traits. This strategy was
successfully used in previous studies with other complex
traits (Cox et al. 2001; Perola et al. 2001; Fisher et al.
2002; Wu et al. 2002), and it even led to gene identi-
fication in recent studies of asthma (Van Eerdewegh et
al. 2002) and inflammatory bowel disease (Hugot et al.
2001; IBD International Genetics Consortium 2001;
Ogura et al. 2001). In the present study, the obtained
results were encouraging, especially in the case of over-
lapping linkage signals in the 16q24.1 region. Given the
expected difficulties in replicating and verifying the re-
sults of a genomewide scan, the complete results avail-
able at our Web site may also help other research groups
to identify regions showing evidence for linkage in an
even larger number of study populations. On the other
hand, the complexity of our results, as exemplified by
some of the regions (see above)—that is, nonadditive
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LOD scores, different informative traits, varying peak
locations, and relatively weak signals—reflects well the
problems of complex traits (Risch and Giuffra 1992;
Lander and Shork 1994; Go¨ring and Terwilliger 2000a),
as well as problems associated with genome scans in
general, including inevitable map and genotyping er-
rors. In addition, population-based differences are likely
to explain part of the picture, although similar problems
can also be seen even when the study samples are col-
lected from the same population, as was demonstrated
by the results of three Finnish type 2 diabetes genome
scans (Mahtani et al. 1996; Ghosh et al. 2000; Wata-
nabe et al. 2000). More refined phenotyping and de-
tailed haplotype mapping is needed to clarify these par-
tially overlapping linkage signals across different traits.
In the linked 16q region, we investigated one obvious
positional and functional candidate gene, the FOXC2
gene. This gene has been proposed to work as an anti-
thrifty gene in hypertriglyceridemia, obesity, and diet-
induced insulin resistance (Cederberg et al. 2001). On
the one hand, thrifty genes are suggested to conserve
energy during periods of famine, and, on the other hand,
they constitute a risk for developing obesity-related con-
ditions, such as type 2 diabetes, when energy is abun-
dant. Although no coding variants were identified in
our sequence analysis of the FOXC2 gene, we found
some evidence of association with an SNP haplotype
including the SNP located in the middle of a well-con-
served putative promoter or a regulative element of
FOXC2. However, caution is needed when interpreting
this result, given the amount of multiple testing. Func-
tional studies of these variants and further studies in
other study samples with additional SNPs are warranted
to obtain a clearer picture of the possible role of FOXC2
in FCHL. Furthermore, we have not excluded the pos-
sibility that the observed linkage (and association) at
this locus may be caused by another nearby gene.
In this study, both parametric and nonparametric link-
age analyses were performed, and, for the fine-mapping
regions, multipoint analyses were performed in addition
to the two-point analyses. We recognize that an impor-
tant question arises as to whether the LOD scores ob-
tained by these different analyses are comparable (Nyholt
2000). The two-point LOD scores were obtained by af-
fecteds-only parametric linkage and nonparametric ASP
analyses, using the Mlink and Sibpair programs of the
Analyze package (Go¨ring and Terwilliger 2000a). The
multipoint results were obtained by parametric location
score and NPL analyses through use of the SimWalk pro-
gram (Sobel and Lange 1996). The LOD scores of the
parametric and nonparametric two-point analyses, as
well as the LOD scores of the parametric multipoint lo-
cation score analyses that are conducted under the as-
sumption of homogeneity, are comparable (Sobel and
Lange 1996; Go¨ring and Terwilliger 2000a; Nyholt
2000). The results from the multipoint NPL analysis rep-
resent scores, not LOD scores. These log (P value)10
scores and the LOD scores of the par- log (P value)10
ametric multipoint location score analysis permitting het-
erogeneity are not directly comparable to the others.
However, we converted the results to P values, and the
P values are provided along with the LOD scores and
scores, to make the results comparable. log (P value)10
The P values for LOD scores detected under homogeneity
were estimated according to the method proposed by
Nyholt (2000), and the P values for LOD scores detected
under heterogeneity were estimated according to the
method proposed by Chiano and Yates (1995). The out-
put of the SimWalk program also provides P values, as
does the two-point ASP analysis using the Sibpair pro-
gram, and these P values are given for these nonpara-
metric methods.
Five binary traits—FCHL and its component traits
TGs, TC, ApoB, and HDL-C—were analyzed because
of their importance in FCHL (Goldstein et al. 1973;
Brunzell et al. 1983). We recognize that this number of
tested traits raises the question of multiple testing. How-
ever, these five traits are closely correlated, making it
difficult to compute a global P value for multiple testing
using, for example, the Bonferroni correction. In gen-
eral, some guidelines have been suggested for encour-
aging or positive LOD scores in genomewide scans
(Lander and Kruglyak 1995). Results can be interpreted
on the basis of the number of times that one would
expect to see such a result at random in a complete
genome scan. A pointwise threshold of a LOD score of
3.3 was proposed for significant linkage, a threshold of
1.9 was proposed for suggestive linkage, and a threshold
of 0.59 was proposed for nominal linkage. These guide-
lines have, however, been challenged by others (Morton
1998). In addition, with the denser map regions, the
increased marker density and information content also
require an increased LOD-score threshold (Wiltshire et
al. 2002). Thus, for a complex disorder such as FCHL,
posing a critical value for a positive LOD score is dif-
ficult. A commonly accepted approach is replication in
an independent study sample. In the present study, both
study samples, the Dutch and the Finnish, supported
the 16q region, although the interpretation of the results
on 2p and 9p is much less straightforward.
In conclusion, the goal of this study was to identify
chromosomal loci for FCHL and related lipid traits TG,
TC, apoB, and HDL-C in a combined data analysis of
study samples from two populations. A locus on chro-
mosome 16q24.1, previously seen with suggestive sta-
tistical significance in the separate genome scans, pro-
vided the most solid evidence for linkage, with a
maximum multipoint LOD score of 3.6 for the low–
HDL-C trait. In addition, loci on chromosomes 2p25.1,
9p23, and 1q21 provided suggestive evidence of linkage
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in the combined data sets and should be targeted for
further analysis.
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